T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up

T2 Biosystems brought on two former Hologic executives to help it ramp up for the commercial rollout of its T2Candida rapid diagnostic assay. Sarah Kalil is the Massachusetts-based 2012 Fierce 15 winner's new chief operating officer, and Steven Scampini is now T2's vice president of engineering. Kalil worked as part of Hologic Corporate Operations, and Scampini was Hologic's senior director of product development. Right now, T2 is in the midst of a pivotal trial for T2Candida that will involve as many as 1,500 patients, and plans call for filing a petition for a de novo/510(k) designation by the 2014 first quarter. Massachusetts General Hospital, Harvard University and MIT's Robert Langer are behind the assay, which uses magnetic resonance technology to help detect the possible presence of Candida in blood or urine within a few hours. Item

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.